Free Trial
NASDAQ:ZBIO

Zenas BioPharma (ZBIO) Stock Price, News & Analysis

Zenas BioPharma logo
$16.26 -0.45 (-2.69%)
As of 04:00 PM Eastern

About Zenas BioPharma Stock (NASDAQ:ZBIO)

Key Stats

Today's Range
$16.17
$16.91
50-Day Range
$9.14
$17.28
52-Week Range
$5.83
$26.25
Volume
99,604 shs
Average Volume
163,277 shs
Market Capitalization
$684.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.67
Consensus Rating
Buy

Company Overview

Zenas BioPharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
31st Percentile Overall Score

ZBIO MarketRank™: 

Zenas BioPharma scored higher than 31% of companies evaluated by MarketBeat, and ranked 815th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Zenas BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Zenas BioPharma has received no research coverage in the past 90 days.

  • Read more about Zenas BioPharma's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Zenas BioPharma is -4.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Zenas BioPharma is -4.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Zenas BioPharma has a P/B Ratio of 2.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Zenas BioPharma's valuation and earnings.
  • Short Interest

    There is no current short interest data available for ZBIO.
  • Short Interest

    There is no current short interest data available for ZBIO.
  • News Sentiment

    Zenas BioPharma has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Zenas BioPharma this week, compared to 10 articles on an average week.
  • MarketBeat Follows

    1 people have added Zenas BioPharma to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Zenas BioPharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.50% of the stock of Zenas BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Zenas BioPharma's insider trading history.
Receive ZBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zenas BioPharma and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ZBIO Stock News Headlines

Tax Drain Deadline: Protect Your Wealth Before September 15th
On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed professionals, retirees, and high-net-worth savers. But the wealthy aren’t just writing checks. They’re moving fast to protect capital and purchasing power using legal, IRS-compliant strategies. American Alternative Assets just released the Mar-A-Lago Accord, a free guide revealing how to reduce Q3 tax exposure and reposition wealth before it’s drained.tc pixel
Zenas BioPharma Reports Q2 2025 Financial Results
See More Headlines

ZBIO Stock Analysis - Frequently Asked Questions

Zenas BioPharma's stock was trading at $7.90 at the beginning of the year. Since then, ZBIO shares have increased by 105.8% and is now trading at $16.26.

Zenas BioPharma, Inc. (NASDAQ:ZBIO) announced its quarterly earnings results on Tuesday, August, 12th. The company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($1.02) by $0.23.

Zenas BioPharma (ZBIO) raised $225 million in an initial public offering (IPO) on Friday, September 13th 2024. The company issued 13,235,294 shares at $17.00 per share.

Top institutional investors of Zenas BioPharma include Federated Hermes Inc. (4.45%), Geode Capital Management LLC (0.89%), Schroder Investment Management Group (0.37%) and Rhumbline Advisers (0.05%).

Shares of ZBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zenas BioPharma investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Trade Desk (TTD), Advanced Micro Devices (AMD), Biosig Technologies (BSGM), Ford Motor (F) and Genius Sports (GENI).

Company Calendar

Last Earnings
8/12/2025
Today
8/28/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ZBIO
Previous Symbol
NASDAQ:ZBIO
CIK
1953926
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

High Price Target
$45.00
Low Price Target
$30.00
Potential Upside/Downside
+122.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.55)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$156.99 million
Net Margins
N/A
Pretax Margin
-1,178.42%
Return on Equity
-59.21%
Return on Assets
-50.56%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.23
Quick Ratio
5.23

Sales & Book Value

Annual Sales
$15 million
Price / Sales
46.24
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.69 per share
Price / Book
2.89

Miscellaneous

Outstanding Shares
42,110,000
Free Float
35,162,000
Market Cap
$693.55 million
Optionable
N/A
Beta
N/A

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:ZBIO) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners